Skip to main content

Advertisement

Table 1 Clinicopathologic characteristics of patients with colorectal oligometastasis to the liver after curative liver resection

From: Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?

Parameters Total (n) With ACT (n, %) Without ACT (n, %) P value
Number of patients 264 200 64  
Age, years
 ≤ 60 164 129 (64.5) 35 (54.7) 0.159
 > 60 100 71 (35.5) 29 (45.3)  
Sex
 Male 171 128 (64.0) 43 (67.2) 0.895
 Female 93 72 (36.0) 21 (32.8)  
Primary tumor location
 Colon 163 126 (63.0) 37 (57.8) 0.457
 Rectum 101 74 (37.0) 27 (42.8)  
Primary tumor differentiation
 Well to moderate 206 155 (77.5) 51 (79.7) 0.713
 Poor 58 45 (22.5) 13 (20.3)  
T stagea
 1–3 157 122 (65.2) 35 (66.5) 0.707
 4 86 65 (34.8) 21 (33.5)  
N stageb
 0 103 78 (42.9) 25 (45.3) 0.814
 1–2 135 104 (57.1) 31 (55.4)  
Timing of metastasis
 Synchronous 171 136 (68.0) 35 (54.7) 0.052
 Metachronous 93 64 (32.0) 29 (45.3)  
Number of metastatic tumors
 1 140 102 (51.0) 38 (59.4) 0.501
 2–3 99 78 (39.0) 21 (32.8)  
 4–5 25 20 (10.0) 5 (7.8)  
Metastases diameter (cm)c
 ≤ 3 173 134 (68.0) 39 (61.9) 0.371
 > 3 87 63 (32.0) 24 (38.1)  
Preoperative CEA (ng/mL)d
 ≤ 50 200 156 (81.7) 44 (73.3) 0.161
 > 50 51 35 (18.3) 16 (26.7)  
Preoperative CA19-9 (U/mL)a
 ≤ 35 166 128 (68.8) 38 (66.7) 0.760
 > 35 77 58 (31.2) 19 (33.3)  
Preoperative chemotherapy
 Yes 122 98 (49.0) 24 (37.5) 0.108
 No 142 102 (51.0) 40 (62.5)  
MSKCC-CRSe
 0–2 162 127 (73.4) 35 (67.3) 0.390
 3–5 63 46 (26.6) 17 (32.7)  
  1. ACT adjuvant chemotherapy, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, MSKCC-CRS Memorial Sloan-Kettering Cancer Center clinical risk score
  2. aData were available for 243 patients
  3. bData were available for 238 patients
  4. cData were available for 260 patients
  5. dData were available for 251 patients
  6. eData were available for 225 patients